In our cohort, 7.05% of the patients carried an alteration in an HR gene, with certain tumors showing increased levels of these alterations, such as breast cancer (9.68%), ovarian cancer (20%) and prostate cancer (17.14%). Moreover, the majority (74.42%) of the HR-positive patients, carried an HR gene mutation in a non BRCA1/2 gene, indicating the necessity of gene panel analysis for the identification of patients eligible for PARPi treatment. Here, BRCA1 is linked to breast cancer.